- Home
- ETNB vs MNKD Comparison
ETNB vs MNKD Comparison
Compare ETNB & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- MNKD
- Stock Information
- Founded
- ETNB 2018
- MNKD 1991
- Country
- ETNB United States
- MNKD United States
- Employees
- ETNB N/A
- MNKD N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- MNKD Biotechnology: Pharmaceutical Preparations
- Sector
- ETNB Health Care
- MNKD Health Care
- Exchange
- ETNB Nasdaq
- MNKD Nasdaq
- Market Cap
- ETNB 1.5B
- MNKD 1.2B
- IPO Year
- ETNB 2019
- MNKD 2004
- Fundamental
- Price
- ETNB $8.08
- MNKD $5.39
- Analyst Decision
- ETNB Strong Buy
- MNKD Strong Buy
- Analyst Count
- ETNB 10
- MNKD 5
- Target Price
- ETNB $27.22
- MNKD $10.80
- AVG Volume (30 Days)
- ETNB 1.3M
- MNKD 5.8M
- Earning Date
- ETNB 11-06-2025
- MNKD 11-06-2025
- Dividend Yield
- ETNB N/A
- MNKD N/A
- EPS Growth
- ETNB N/A
- MNKD 149.32
- EPS
- ETNB N/A
- MNKD 0.11
- Revenue
- ETNB N/A
- MNKD $301,736,000.00
- Revenue This Year
- ETNB N/A
- MNKD $16.36
- Revenue Next Year
- ETNB N/A
- MNKD $20.34
- P/E Ratio
- ETNB N/A
- MNKD $50.42
- Revenue Growth
- ETNB N/A
- MNKD 21.48
- 52 Week Low
- ETNB $4.16
- MNKD $3.38
- 52 Week High
- ETNB $11.84
- MNKD $7.63
- Technical
- Relative Strength Index (RSI)
- ETNB 35.99
- MNKD 63.64
- Support Level
- ETNB $7.84
- MNKD $5.25
- Resistance Level
- ETNB $9.47
- MNKD $5.77
- Average True Range (ATR)
- ETNB 0.45
- MNKD 0.29
- MACD
- ETNB -0.08
- MNKD -0.01
- Stochastic Oscillator
- ETNB 13.96
- MNKD 54.75
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.